Small Molecules

17 July 2024

Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity

16 July 2024

Novo Holdings leads $100 million Series C financing of Asceneuron to advance groundbreaking therapy for Alzheimer’s disease

16 July 2024

Evommune Announces Positive Proof-of-Concept Clinical Trial Results for its MRGPRX2 Antagonist (EVO756)

15 July 2024

Nocion Therapeutics Presents Data on Preclinical and Clinical Development of Taplucainium, a Novel, Charged Sodium Channel Blocker, as a potential treatment for Chronic Cough at the 13th London International Cough Symposium

15 July 2024

Rznomics Inc. Secures Australian Clinical Trial Notification for RHO-targeted Splicing Ribozyme-based RNA Editing Therapy for Retinitis Pigmentosa

13 July 2024

AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis

13 July 2024

Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics

12 July 2024

First Patient Enrolled in a Phase 2 Study in Patients with Type 2 Diabetes with Olatec’s NLRP3 Inhibitor, Dapansutrile

12 July 2024

Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron

12 July 2024

Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247

11 July 2024

Skyhawk Therapeutics Announces Positive Topline Results from Parts A and B of its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease, Reaching 72% Huntingtin mRNA Reduction

11 July 2024

MEKanistic Therapeutics Inc.’s First-in-Class Dual EGFR and PI3K Investigational Therapy, MTX-531, Demonstrates Significant Tolerability and Durable Tumor Regressions in Preclinical Cancer Models

11 July 2024

Rgenta Therapeutics Announces FDA Clearance of IND Application for RGT-61159, an Oral Small Molecule RNA Modulator Designed to Halt Disease-Driver MYB Production in Adenoid Cystic Carcinoma (ACC) and Colorectal Cancer (CRC)

10 July 2024

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

9 July 2024

Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC

8 July 2024

BioCity announces its endothelin receptor A selective antagonist SC0062 met the primary endpoint in IgA nephropathy in 2-SUCCEED trial: a randomized, double-blind, placebo-controlled Phase 2 trial

5 July 2024

Tagrisso with the addition of chemotherapy approved in the EU as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer

4 July 2024

Johnson & Johnson Receives Approval from U.S. FDA and European Commission for SIRTURO® (bedaquiline)

3 July 2024

Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH)

3 July 2024

Satellos Presents Preliminary Data Showing Muscle Repair and Regeneration from SAT-3247 Treatment in Canine Model of Duchenne Muscular Dystrophy (“DMD”)

3 July 2024

Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis

1 July 2024

Eirion Therapeutics Announces Initiation of First-in-Human Clinical Trial Evaluating Topical ET-02 for the Treatment of Androgenic Alopecia

1 July 2024

Radionetics Oncology Enters Into Strategic Agreement With Lilly

1 July 2024

Circle Pharma files first Investigational New Drug application for first-in-class oral cyclin A/B RxL inhibitor for treatment of advanced solid tumors

1 July 2024

Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension

1 July 2024

TauRx Submits UK Marketing Authorisation Application for HMTM as a Treatment for Alzheimer’s Disease

1 July 2024

Ubix Therapeutics and Yuhan Announce Exclusive License Agreement for UBX-103, an Oral Small Molecule AR Degrader for Treatment of Metastatic Castration Resistant Prostate Cancer

28 June 2024

BridGene Biosciences Announces Dosing of First Patient in Phase 1 Study Evaluating Novel TEAD Inhibitor BGC515 in Advanced Solid Tumors

28 June 2024

Pierre Fabre Laboratories announce granting of European marketing authorization for OBGEMSA™ (vibegron) in overactive bladder.

28 June 2024

Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

TL1A Inhibitor Pipeline Review

Bispecific Antibodies for Immuno-Oncology & Other Diseases

Blockbuster Biologics 2018: Sales of Recombinant Therapeutic Antibodies & Proteins

Adalimumab (Humira) Biosimilars Pipeline Review

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Blockbuster Biologics 2019: Sales of Recombinant Therapeutic Antibodies & Proteins

GPC3-Targeted Immunotherapy Pipeline Review

Report Package: Bispecific Antibodies